KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $136.5 million.

  • Emergent BioSolutions' Total Current Liabilities fell 4062.64% to $136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.5 million, marking a year-over-year decrease of 4062.64%. This contributed to the annual value of $162.4 million for FY2024, which is 7506.53% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Total Current Liabilities is $136.5 million, which was down 4062.64% from $127.1 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Total Current Liabilities ranged from a high of $1.2 billion in Q4 2022 and a low of $111.9 million during Q1 2025
  • Over the past 5 years, Emergent BioSolutions' median Total Current Liabilities value was $370.2 million (recorded in 2021), while the average stood at $460.4 million.
  • Per our database at Business Quant, Emergent BioSolutions' Total Current Liabilities surged by 38784.11% in 2023 and then crashed by 8224.37% in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Total Current Liabilities stood at $374.0 million in 2021, then skyrocketed by 228.58% to $1.2 billion in 2022, then tumbled by 47.0% to $651.3 million in 2023, then plummeted by 75.07% to $162.4 million in 2024, then fell by 15.95% to $136.5 million in 2025.
  • Its last three reported values are $136.5 million in Q3 2025, $127.1 million for Q2 2025, and $111.9 million during Q1 2025.